1
|
Schetelig J, Baldauf H, Heidenreich F, Hoogenboom JD, Spellman SR, Kulagin A, Schroeder T, Sengeloev H, Dreger P, Forcade E, Vydra J, Wagner-Drouet EM, Choi G, Paneesha S, Miranda NAA, Tanase A, de Wreede LC, Lange V, Schmidt AH, Sauter J, Fein JA, Bolon YT, He M, Marsh SGE, Gadalla SM, Paczesny S, Ruggeri A, Chabannon C, Fleischhauer K. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight. Front Immunol 2024; 15:1350470. [PMID: 38629074 PMCID: PMC11019434 DOI: 10.3389/fimmu.2024.1350470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 03/04/2024] [Indexed: 04/19/2024] Open
Abstract
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor's Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard. In the past decade, different models have been proposed aiming at maximizing NK cell activation by activating KIR-ligand interactions or minimizing inhibitory KIR-ligand interactions. Alternative classifications intended predicting outcome after alloHCT by donor KIR-haplotypes. In the present study, we aimed at validating proposed models and exploring more classification approaches. To this end, we analyzed samples stored at the Collaborative Biobank from HLA-compatible unrelated stem cell donors who had donated for patients with acute myeloid leukemia (AML) or myelodysplastic neoplasm (MDS) and whose outcome data had been reported to EBMT or CIBMTR. The donor KIR genotype was determined by high resolution amplicon-based next generation sequencing. We analyzed data from 5,017 transplants. The median patient age at alloHCT was 56 years. Patients were transplanted for AML between 2013 and 2018. Donor-recipient pairs were matched for HLA-A, -B, -C, -DRB1, and -DQB1 (79%) or had single HLA mismatches. Myeloablative conditioning was given to 56% of patients. Fifty-two percent of patients received anti-thymocyte-globulin-based graft-versus-host disease prophylaxis, 32% calcineurin-inhibitor-based prophylaxis, and 7% post-transplant cyclophosphamide-based prophylaxis. We tested several previously reported classifications in multivariable regression analyses but could not confirm outcome associations. Exploratory analyses in 1,939 patients (39%) who were transplanted from donors with homozygous centromeric (cen) or telomeric (tel) A or B motifs, showed that the donor cen B/B-tel A/A diplotype was associated with a trend to better event-free survival (HR 0.84, p=.08) and reduced risk of non-relapse mortality (NRM) (HR 0.65, p=.01). When we further dissected the contribution of B subtypes, we found that only the cen B01/B01-telA/A diplotype was associated with a reduced risk of relapse (HR 0.40, p=.04) while all subtype combinations contributed to a reduced risk of NRM. This exploratory finding has to be validated in an independent data set. In summary, the existing body of evidence is not (yet) consistent enough to recommend use of donor KIR genotype information for donor selection in routine clinical practice.
Collapse
Affiliation(s)
- Johannes Schetelig
- Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany
- Clinical Trials Unit, DKMS Group, Dresden, Germany
| | | | - Falk Heidenreich
- Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany
- Clinical Trials Unit, DKMS Group, Dresden, Germany
| | | | - Stephen R. Spellman
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program (NMDP), Minneapolis, MN, United States
| | - Alexander Kulagin
- RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | - Thomas Schroeder
- Klinik für Hämatologie und Stammzelltransplantation, Universitätsklinikum Essen, Essen, Germany
| | - Henrik Sengeloev
- Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
| | - Peter Dreger
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Edouard Forcade
- Service Hématologie clinique de Thérapie cellulaire, Centre Hospitalier Universitaire Bordeaux, Université de Bordeaus, Bordeaux, France
| | - Jan Vydra
- Transplant Unit and Intensive Care Unit, Institute of Hematology and Bood Transfusion, Prague, Czechia
| | - Eva Maria Wagner-Drouet
- Center for Cellular Immunotherapy and Stem Cell Transplantation, Third Medical Department, Hematology and Oncology, University Cancer Center Mainz, Mainz, Germany
| | - Goda Choi
- University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Shankara Paneesha
- Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - Nuno A. A. Miranda
- Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
| | - Alina Tanase
- Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | | | | | | | | | - Joshua A. Fein
- Department of Hematology & Medical Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, United States
| | - Yung-Tsi Bolon
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program (NMDP), Minneapolis, MN, United States
| | - Meilun He
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program (NMDP), Minneapolis, MN, United States
| | - Steven G. E. Marsh
- Anthony Nolan Research Institute, Royal Free Hospital, London & Cancer Institute, University College London, London, United Kingdom
| | - Shahinaz M. Gadalla
- National Cancer Institute, Division of Cancer Epidemiology & Genetics, Bethesda, MD, United States
| | - Sophie Paczesny
- Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States
| | | | - Christian Chabannon
- Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, Marseille, France
| | | |
Collapse
|
2
|
Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart JE, Hoogenboom JD, Urbano-Ispizua A, Peters S, Kuball J, Kröger N, Sureda A, Chabannon C, Haanen J, Pedrazzoli P. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey. Ann Oncol 2024; 35:404-406. [PMID: 38145867 DOI: 10.1016/j.annonc.2023.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 12/09/2023] [Accepted: 12/17/2023] [Indexed: 12/27/2023] Open
Affiliation(s)
- P Comoli
- Cell Factory and Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | | | - A Ruggeri
- Pediatric Hematology and BMT Unit, San Raffaele Scientific Institute, Milan, Italy
| | - U Koehl
- Institute of Clinical Immunology and Fraunhofer Institute for Cell Therapy and Immunology, Leipzig
| | - F Lordick
- Medical Oncology, Universitätsklinikum Leipzig, Leipzig, Germany
| | | | | | - A Urbano-Ispizua
- Hematology Department, Clinic University Hospital, Barcellona, Spain
| | - S Peters
- Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - J Kuball
- Department of Hematology and Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands
| | - N Kröger
- University Medical Center Hamburg, Hamburg, Germany
| | - A Sureda
- Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain
| | - C Chabannon
- Centre de Thérapie Cellulaire & Centre d'Investigations Cliniques en Biothérapies Inserm CBT-1409, Institut Paoli-Calmettes, Marseille, Cedex, France
| | - J Haanen
- Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - P Pedrazzoli
- Oncology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Dept of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
| |
Collapse
|
3
|
Worel N, Ljungman P, Verheggen ICM, Hoogenboom JD, Knelange NS, Eikema DJ, Sánchez-Ortega I, Riillo C, Centorrino I, Averbuch D, Chabannon C, de la Camara R, Kuball J, Ruggeri A. Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP). Bone Marrow Transplant 2023; 58:1348-1356. [PMID: 37673982 DOI: 10.1038/s41409-023-02099-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Revised: 08/12/2023] [Accepted: 08/23/2023] [Indexed: 09/08/2023]
Abstract
The COVID-19 pandemic has had a significant impact on medical practices, including the delivery of allogeneic hematopoietic cell transplantation (HCT). In response, transplant centers have made changes to their procedures, including an increased use of cryopreservation for allogeneic haematopoietic progenitor cell (HPC) grafts. The use of cryopreserved grafts for allogeneic HCT has been reviewed and analysed in terms of potential benefits and drawbacks based on existing data on impact on cell subsets, hematological recovery, and clinical outcomes of approximately 2000 patients from different studies. A survey of European Society for Blood and Marrow Transplantation centers was also conducted to assess changes in practice during the pandemic and any unnecessary burdens on HPC donors. Before the pandemic, only 7.4% of transplant centers were routinely cryopreserving HPC products, but this percentage increased to 90% during the pandemic. The results of this review and survey suggest that cryopreservation of HPC grafts is a viable option for allogeneic HCT in certain situations, but further research is needed to determine long-term effects and ethical discussions are required to balance the needs of donors and patients when using frozen allografts.
Collapse
Affiliation(s)
- N Worel
- Medical University Vienna; Department. of Transfusion Medicine and Cell Therapy, Vienna, Austria.
| | - P Ljungman
- Department. of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge and Div. of Hematology, Department. of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | | | | | | | - D-J Eikema
- EBMT Statistical Unit, Leiden, Netherlands
| | | | - C Riillo
- Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
| | - I Centorrino
- Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
| | - D Averbuch
- Faculty of Medicine, Hebrew University of Jerusalem; Hadassah Medical Center, Jerusalem, Israel
| | - C Chabannon
- Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT, 1409, Marseille, France
| | | | - J Kuball
- Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
| | - A Ruggeri
- Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy
| |
Collapse
|
4
|
Battipaglia G, Mooyaart JE, Meyer R, Mohty M, Sadowska-Klasa A, Goloshchapov O, Locatelli F, Styczynski J, Pavlu J, Dybko J, Bronin G, Salmenniemi U, Jindra P, Hoogenboom JD, Kuball J, Ruggeri A, Malard F. Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT. Bone Marrow Transplant 2023; 58:1419-1421. [PMID: 37789073 DOI: 10.1038/s41409-023-02115-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 09/16/2023] [Accepted: 09/22/2023] [Indexed: 10/05/2023]
Affiliation(s)
- Giorgia Battipaglia
- Department of Clinical Hematology and Surgery, Division of Hematology, Federico II University of Naples, Naples, Italy.
| | | | - Ralf Meyer
- Dortmunder Centrum für Zelltransplantation (DCZ), Dortmund, Germany
| | - Mohamad Mohty
- Sorbonne Université; Centre de Recherche Saint-Antoine INSERM UMRs938; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
| | - Alicja Sadowska-Klasa
- Department of Hematology and Transplantology, Medical University of Gdansk, Gdańsk, Poland
| | - Oleg Goloshchapov
- RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | | | - Jan Styczynski
- Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
| | | | - Jaroslaw Dybko
- Department of Hematology and Transplantology, Lower Silesian Center of Oncology, Wroclaw, Poland
| | | | - Urpu Salmenniemi
- Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki University Hospital, Helsinki, Finland
| | - Pavel Jindra
- Charles University Hospital, Pilsen, Czech Republic
| | | | - Jurgen Kuball
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Annalisa Ruggeri
- Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy
| | - Florent Malard
- Sorbonne Université; Centre de Recherche Saint-Antoine INSERM UMRs938; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
| |
Collapse
|
5
|
de Witte MA, Mooyaart JE, Hoogenboom JD, Chabannon C, Malard F, Ruggeri A, Kuball J. Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party. Bone Marrow Transplant 2023:10.1038/s41409-023-01953-1. [PMID: 36934148 DOI: 10.1038/s41409-023-01953-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 02/27/2023] [Accepted: 03/08/2023] [Indexed: 03/20/2023]
Affiliation(s)
- M A de Witte
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | | | - C Chabannon
- Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapies, Université d'Aix-Marseille, Inserm, CBT 1409, Marseille, France
| | - F Malard
- Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine (CRSA), INSERM, Paris, France
| | - A Ruggeri
- San Raffaele Scientific Institute, Hematology and Bone marrow Transplantation Unit, Milan, Italy
| | - J Kuball
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
| |
Collapse
|
6
|
Greco R, Hoogenboom JD, Bonneville EF, Anagnostopoulos A, Cuoghi A, Dalle JH, Weissinger EM, Lang P, Galaverna F, Martino M, Maschan A, Mauz-Körholz C, Noviello M, Passweg J, Peccatori J, Rovira M, Solano C, Veelken H, Velardi A, Wagner-Drouet EM, Zhang X, Ciceri F, Bonini C, Vago L, Ruggeri A, Chabannon C. Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party. Bone Marrow Transplant 2023; 58:603-606. [PMID: 36813866 PMCID: PMC9944777 DOI: 10.1038/s41409-023-01939-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Revised: 02/05/2023] [Accepted: 02/14/2023] [Indexed: 02/24/2023]
Affiliation(s)
- Raffaella Greco
- Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
| | | | - Edouard F. Bonneville
- grid.476306.0EBMT Leiden Study Unit, Leiden, The Netherlands ,grid.10419.3d0000000089452978Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Angela Cuoghi
- grid.413363.00000 0004 1769 5275Azienda Ospedaliero Universitaria di Modena Policlinico, Modena, Italy
| | | | - Eva M. Weissinger
- grid.10423.340000 0000 9529 9877Hannover Medical School, Hannover, Germany
| | - Peter Lang
- grid.411544.10000 0001 0196 8249University Hospital, Tuebingen, Germany
| | - Federica Galaverna
- grid.414125.70000 0001 0727 6809IRRCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
| | - Massimo Martino
- Grande Ospedale Metropolitano Bianchi Melacrino Morelli - Centro Unico Trapianti A. Neri, Reggio Calabria, Italy
| | - Alexei Maschan
- Federal Research Center for Pediatric Hematology, Moscow, Russia
| | - Christine Mauz-Körholz
- grid.8664.c0000 0001 2165 8627Justus-Liebig-University Giessen, Giessen, Germany ,grid.9018.00000 0001 0679 2801Medical Faculty of the Martin-Luther-University of Halle, Halle, Germany
| | - Maddalena Noviello
- grid.15496.3f0000 0001 0439 0892Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Disease, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milano, Italy
| | - Jakob Passweg
- grid.410567.1University Hospital, Basel, Switzerland
| | - Jacopo Peccatori
- grid.15496.3f0000 0001 0439 0892Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
| | - Montserrat Rovira
- grid.410458.c0000 0000 9635 9413BMT Unit, Hematology Department, ICMHO, IDIBAPS Hospital Clinic, Josep Carreras Institute, Barcelona, Spain
| | - Carlos Solano
- grid.411308.fHospital Clínico Universitario. University of Valencia, Valencia, Spain
| | - Hendrik Veelken
- grid.10419.3d0000000089452978Leiden University Hospital, Leiden, Netherlands
| | - Andrea Velardi
- grid.9027.c0000 0004 1757 3630Bone Marrow Transplantation Program, Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | | | - Xi Zhang
- grid.410570.70000 0004 1760 6682Medical center of hematology, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Fabio Ciceri
- grid.15496.3f0000 0001 0439 0892Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy ,grid.15496.3f0000 0001 0439 0892Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milano, Italy
| | - Chiara Bonini
- grid.15496.3f0000 0001 0439 0892Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Disease, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milano, Italy ,grid.15496.3f0000 0001 0439 0892Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milano, Italy
| | - Luca Vago
- grid.15496.3f0000 0001 0439 0892Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy ,grid.15496.3f0000 0001 0439 0892Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milano, Italy ,grid.18887.3e0000000417581884Unit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milano, Italy
| | - Annalisa Ruggeri
- grid.15496.3f0000 0001 0439 0892Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
| | - Christian Chabannon
- grid.5399.60000 0001 2176 4817Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d’Investigations Cliniques en Biothérapies, Université d’Aix-Marseille, Inserm CBT, 1409 Marseille, France
| |
Collapse
|
7
|
Santoro N, Mooyaart JE, Devillier R, Koc Y, Vydra J, Castagna L, Gülbas Z, Martin JD, Araujo MC, Kulagin A, Arat M, Arroyo CH, Martelli MP, Di Ianni M, Hoogenboom JD, de Wreede LC, Ruggeri A, Chabannon C. Correction: Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party. Bone Marrow Transplant 2023; 58:119-120. [PMID: 36517566 DOI: 10.1038/s41409-022-01855-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Nicole Santoro
- Department of Hematology and Oncology, Ospedale Civile "Santo Spirito", Pescara, Italy.
| | | | - Raynier Devillier
- Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, & Centre de Recherches en Cancérologie de Marseille (CRCM), Inserm UMR 1068, Université d'Aix-Marseille, Marseille, France
| | - Yener Koc
- Medicana International Hospital Istanbul, Istanbul, Turkey
| | - Jan Vydra
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | | | - Zafer Gülbas
- Anadolu Medical Center Hospital, Kocaeli, Turkey
| | - José Diez Martin
- Servicio de Hematología Hospital G. Universitario Gregorio Marañon, Instituto de Investigación sanitaria Gregorio Marañon, Department of Medicine Universidad Complutense, Madrid, Spain
| | | | - Alexander Kulagin
- RM Gorbacheva Research Institute, Pavlov University, St, Petersburg, Russia
| | - Mutlu Arat
- Demiroglu Bilim University Istanbul Florence Nightingale Hospital Istanbul, Istanbul, Turkey
| | | | - Maria Paola Martelli
- Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy
| | - Mauro Di Ianni
- Department of Hematology and Oncology, Ospedale Civile "Santo Spirito", Pescara, Italy
| | | | | | - Annalisa Ruggeri
- San Raffaele Scientific Institute, Hematology and Bone marrow Transplantation unit, Milan, Italy
| | - Christian Chabannon
- Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer & Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT, 1409, Marseille, France
| |
Collapse
|
8
|
Ruggeri A, de Wreede LC, Müller CR, Crivello P, Bonneville EF, Petersdorf EW, Socié G, Dubois V, Niittyvuopio R, Peräsaari J, Yakoub-Agha I, Cornelissen JJ, Wieten L, Gedde-Dahl T, Forcade E, Crawley CR, Marsh SG, Gandemer V, Tholouli E, Bulabois CE, Huynh A, Choi G, Deconinck E, Itäla-Remes M, Lenhoff S, Bengtsson M, Johansson JE, van Gorkom G, Hoogenboom JD, Vago L, Rocha V, Bonini C, Chabannon C, Fleischhauer K. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation. Haematologica 2022; 108:645-652. [PMID: 35546480 PMCID: PMC9890035 DOI: 10.3324/haematol.2021.280055] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Indexed: 02/03/2023] Open
Affiliation(s)
- Annalisa Ruggeri
- San Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit, Milan, Italy,Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, the Netherlands
| | | | | | - Pietro Crivello
- Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany
| | | | | | | | | | | | - Juha Peräsaari
- Clinical Laboratory Services, Histocompatibility Testing, Finnish Red Cross Blood Service, Helsinki, Finland
| | | | | | - Lotte Wieten
- Transplantation Immunology, Maastricht University Medical Center, Maastricht, the Netherlands
| | | | | | | | - Steven G.E. Marsh
- Anthony Nolan Research Institute and UCL Cancer Institute, Royal Free Campus, London, UK
| | | | | | | | - Anne Huynh
- CHU - Institut Universitaire du Cancer Toulouse, Toulouse, France
| | - Goda Choi
- University Medical Center Groningen (UMCG), Groningen, the Netherlands
| | | | | | | | - Mats Bengtsson
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | | | | | | | - Luca Vago
- San Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit, Milan, Italy,Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, the Netherlands
| | - Vanderson Rocha
- Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31) of the Service of Hematology and Cell Therapy, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, SP, Brazil
| | - Chiara Bonini
- San Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit, Milan, Italy,Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, the Netherlands
| | - Christian Chabannon
- Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, the Netherlands,Institut PaoliCalmettes, Centre de Lutte Contre le Cancer, Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT 1409, Marseille, France
| | - Katharina Fleischhauer
- Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, The Netherlands; Institute for Experimental Cellular Therapy, University Hospital Essen, Essen.
| |
Collapse
|
9
|
Ghorashian S, Malard F, Yüksel MK, Mauff K, Hoogenboom JD, Urbano-Ispizua A, Kuball J, de la Camara R, Ljungman P, Ruggeri A, Chabannon C. Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT. Bone Marrow Transplant 2021; 57:299-301. [PMID: 34802048 PMCID: PMC8605455 DOI: 10.1038/s41409-021-01483-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 09/15/2021] [Accepted: 09/23/2021] [Indexed: 11/10/2022]
Affiliation(s)
- Sara Ghorashian
- Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK.
| | - Florent Malard
- Service d'hématologie clinique et de thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France
| | - Meltem Kurt Yüksel
- Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
| | - Katya Mauff
- EBMT Statistical Unit, Leiden, The Netherlands
| | | | | | - Jürgen Kuball
- Department of Hematology, Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | | | - Per Ljungman
- Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
| | | | - Christian Chabannon
- Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT 1409, Marseille, France
| |
Collapse
|